Clinical Trials on ER/Progressive Response (PR) Refractory to Prior Hormonal Treatment

Total 4 results

  • Synta Pharmaceuticals Corp.
    Completed
    An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer (Enchant)
    Breast Cancer | Triple Negative Breast Cancer | HER-2 Positive Breast Cancer | ER/Progressive Response (PR) + Refractory to Prior Hormonal Treatment
    Spain, United States, Argentina, Belgium, Brazil, Korea, Republic of, Peru, United Kingdom
  • Gruppo Italiano Malattie EMatologiche dell'Adulto
    Completed
    GIMEMA CLL0809 Study (BendOfa) (BendOfa)
    Patients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or | Patients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment Lines
    Italy
  • Selcuk University
    Unknown
    Endometrial Biopsy as Diagnostic Method for Endometriosis and Endometrioma
    Women in the Reproductive Age Group | Undergoing Laparoscopy for Pelvic Pain and/or Infertility | Not Currently Receiving Hormonal Treatment for at Least 3 Months Prior to Laparoscopy.
    Turkey
  • RTI International
    Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators
    Enrolling by invitation
    Early Check: Expanded Screening in Newborns
    Primary Hyperoxaluria Type 3 | Diabetes Mellitus | Hemophilia A | Hemophilia B | Hereditary Fructose Intolerance | Cystic Fibrosis | Factor VII Deficiency | Phenylketonurias | Sickle Cell Disease | Dravet Syndrome | Duchenne Muscular Dystrophy | Prader-Willi Syndrome | Fragile X Syndrome | Chronic Granulomatous Disease and other conditions
    United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe